NCT06976918 Research Platform Myelofibrosis and Anemia
| NCT ID | NCT06976918 |
| Status | Recruiting |
| Phase | — |
| Sponsor | iOMEDICO AG |
| Condition | Primary Myelofibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-02-19 |
| Primary Completion | 2031-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-02-19 with a primary completion date of 2031-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively). * Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician. * Start of first or subsequent systemic treatment for MF. * Informed consent and registration for the GSG-MPN Bioregistry. * Willingness and capability to participate in PRO assessment. * Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment. Exclusion Criteria: * No systemic therapy for diagnosed primary or secondary MF. * Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.
Contact & Investigator
Konstanze Döhner, Prof. Dr. med.
STUDY CHAIR
University Hospital Ulm, Germany
Frequently Asked Questions
Who can join the NCT06976918 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Myelofibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06976918 currently recruiting?
Yes, NCT06976918 is actively recruiting participants. Contact the research team at info@iomedico.com for enrollment information.
Where is the NCT06976918 trial being conducted?
This trial is being conducted at Multiple Locations, Germany.
Who is sponsoring the NCT06976918 clinical trial?
NCT06976918 is sponsored by iOMEDICO AG. The principal investigator is Konstanze Döhner, Prof. Dr. med. at University Hospital Ulm, Germany. The trial plans to enroll 200 participants.